secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001739410-23-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio Q2 net loss $18.6M; cash $137.8M; CEO transition to Stephen Uden
-------------------------------------------------------------------------

- Net loss $18.6M ($0.46/sh) vs $17.6M ($0.57/sh) in Q2 2022; R&D expense $13.1M, up from $10.1M.
- Cash, equivalents and marketable securities $137.8M as of June 30, providing runway into 1Q 2025.
- RLYB212 Phase 1b proof-of-concept met endpoint; multiple-dose cohort data and tox results expected in 4Q 2023.
- RLYB116 Phase 1 MAD study initial data (safety, PK, PD) and indication strategy expected in 4Q 2023.
- Effective Aug 1, Stephen Uden became CEO; Martin Mackay appointed Executive Chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000173941023000004/0001739410-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000173941023000004/rlyb-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001739410-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer